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Abstract
Background. Numerous studies have shown a role of the hepatocyte growth factor (HGF) as a ligand for 
the MET receptor in promoting aggressiveness in myeloma cells.
Objectives. The aim of this study was to confirm the presence of the MET receptor in myeloma cell lines, 
to establish a stable lentiviral construct directed against MET receptor mRNA and then to evaluate the effect 
of blocking MET receptor expression both in vitro and in vivo.
Material and methods. The U266 and INA6 cells were transduced using a lentiviral vector carrying 
siRNA to achieve the reduction of MET receptor expression. The ocular sinus of NOD/SCID mice was injected 
with wt-U266, shMET-U266 and shLacZ-U266 cells.
Results. MET receptor expression was demonstrated in all tested myeloma cell lines. Blocking the HGF/MET 
axis did not affect the growth of transduced U266 and INA6 cell lines. The inoculation of NOD/SCID mice with 
myeloma cells with reduced expression of MET led to increased survival of the animals.
Conclusions. MET receptor expression was constituently expressed in all tested myeloma cell lines. A lenti-
viral construct can effectively reduce the expression of the MET receptor in myeloma cells. Further studies are 
necessary to evaluate the effect of the reduction of MET receptor expression in multiple myeloma, focusing 
on animal models with a larger test group size.
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Multiple myeloma (MM) is a plasma cell malignancy 
characterized by uncontrolled proliferation of clonal plasma 
cells manifested clinically by increased secretion of mono- 
clonal immunoglobulins or light chains. Over the past de-
cade, new therapeutic agents have been incorporated into 
the treatment algorithm for patients with MM, increasing 
their survival rates.1–3 Further research into new treat-
ments for MM is essential in order to improve the survival 
of patients. One potential target for MM therapy is the 
hepatocyte growth factor (HGF)/mesenchymal-epithelial 
transition (MET) axis.4
HGF belongs to the plasminogen protein family. Under 
physiological conditions, HGF can be produced by fibro-
blasts, fat collecting liver cells, bone marrow stromal cells, 
endothelial, and epithelial cells. HGF is the only known 
ligand of the MET receptor. The MET receptor is a tyro-
sine kinase receptor. It is composed of an extracellular 50 
kD α chain and a transmembrane 140 kD β chain. HGF 
binding to the MET receptor results in tyrosine phosphor-
ylation of the c-terminal portion, leading to the recruit-
ment of adaptive and signaling proteins, and the activation 
of multiple signal transduction pathways. This activa-
tion results in the migration, mitosis and morphogenesis 
of multiple cell lines, and excessive activation has been 
implicated in the pathogenesis of many cancers.5,6
In patients with MM who showed elevated levels of HGF, 
there is a direct correlation between serum HGF levels and 
aggressiveness of the disease.4,7 The prognosis of patients 
with MM is usually worse in the presence of high levels 
of HGF.8–10 Among the many factors activating myeloma 
cells, HGF is one of the main factors and the presence 
of the MET receptor is a common finding in myeloma cells, 
both at the mRNA and protein levels.11,12 HGF is secreted by 
cells of the bone marrow stroma, thus allowing for autocrine 
and paracrine regulation of tumor cells, stimulates prolifera-
tion and inhibits apoptosis of myeloma cells.11 HGF-induced 
IL-11 secretion from osteoblastic cells may contribute to 
osteolysis seen in a majority of patients with MM.13
Numerous studies have shown a role of HGF/MET axis 
in promoting aggressiveness in myeloma cells. The aim 
of our study was to confirm the presence of the MET recep-
tor in myeloma cell lines and to establish a stable lentiviral 
construct directed against MET receptor mRNA. An addi-
tional goal was to determine whether silencing of the MET 
receptor would have an impact on the growth of myeloma 
cells in vitro and life expectancy of mice inoculated with 
transduced myeloma cells in vivo.
Material and methods
Myeloma cell lines
Myeloma cell lines INA6 and U266 (American Type Cul-
ture Collection, Manassas, USA) were cultured in RPMI 1640 
medium (Gibco BRL, ThermoFisher Scientific, Waltham, 
USA) and supplemented with fetal bovine serum (FBS, 10% 
and 15%, respectively) (PAA Laboratories, GE Healthcare 
Bio-Sciences Austria GmbH, Pasching, Austria), 2 mmol 
L-glutamine, and 100 IU/mL penicillin and 10  µg/mL 
streptomycin (Gibco BRL), at 37°C in an atmosphere of 5% 
CO2 with 95% humidity. Additionally, INA6 required the 
presence of IL-6 at the concentration of 2 ng/mL.
Assessment of gene expression  
by real-time polymerase chain reaction
RNA was isolated using RNeasy Mini Kit (Qiagen, Va-
lencia, USA). The concentration and purity of the obtained 
RNA was assessed by measuring absorbance at a wave-
length of 260 and 280 nm, using a DU 640B spectropho-
tometer (Beckman Coulter, Fullerton, USA). RNA was 
transcribed into cDNA using MMLV reverse transcrip-
tase (Promega, Madison, USA) and non-specific primers, 
called random primers, (Promega). The analysis of gene 
expression was performed by quantitative PCR in real time 
(qRT-PCR) based on specific TaqMan probes (Applied Bio-
systems, Foster City, USA), using an ABI PRISM 7300 Se-
quence Detection System (Applied Biosystems). The com-
ponents of the reaction mixture used in the qRT-PCR 
were: TaqMan PCR Master Mix 25 μL, cDNA 100 ng, 
20× probe 2.5 μL, water added until final volume was 50 μL. 
Probes used for qRT-PCR were manufactured by Applied 
Biosystems accordingly: TaqMan MET Hs01565589_m1 
and GAPDH Hs99999905_m1. To calculate results, we 
analyzed relative gene expression using a ΔΔCt calcula-
tion, based on the comparison values of Ct for the test and 
control gene. We used mRNA isolated from umbilical cord 
blood mononuclear cells as a negative control.
Determination of the MET receptor 
presence
Immunohistochemical staining was used to determine 
the presence of the MET receptor by means of cytospin 
preparations. Preparations were stained using monoclonal 
anti-MET antibodies (1:100 dilution) visualized with the 
DAKO LSAB2 visualization system and kit (DakoCytoma-
tion, Glostrup, Denmark). In order to visualize the antigen-
antibody reaction, 1 drop of streptavidin was added, and 
then chromogen was used as an activating agent. The ob-
tained preparations were stained with hematoxylin and 
embedded in glycerol gel. Samples were evaluated using 
a light microscope produced by Olympus (Tokyo, Japan).
Transfection of myeloma cell lines  
U266 and INA6
Separate test tubes were prepared according to the fol-
lowing specifications: Lipofectamine 2000 in a solution 
of 50 mL OptiMEM I medium (Invitrogen, ThermoFish-
er Scientific, Waltham, USA) and 1 μg siRNA in 50 mL 
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OptiMEM I medium without FBS or antibiotics. These 
agents were combined and allowed to stand for 20 min to 
form 2000 siRNA-lipofectamine complexes.
Cell lines U266 and INA6 were transduced using a lentivi-
ral vector carrying siRNA directed against MET to achieve 
the reduction of gene expression, and LacZ as a control to 
confirm proper action of the receptor. The lentiviral vector 
used for the experiments was based on a 19-nucleotide se-
quence of siRNA directed against MET 5’-CCG AGA AGU 
AUG UGA UGA ATT-3’. Cell lines U266 and INA6 were 
seeded at a concentration of 3 × 104, and converted using 
lentiviral transduction. Ten μL viral particles suspended in 
1 mL RPMI with 10% FBS was added to the cells in the pres-
ence of 6 mg/mL hexadimethrine bromide (Sigma-Aldrich 
Co., St. Louis, USA). After 48 h, blasticidin was introduced 
(10 µg/mL for the U266 line and 4 µg/mL for the INA6 line). 
After 12 days, dead or apoptotic MM cells not resistant to 
blasticidin were observed. We established a naming conven-
tion for these cells by adding wt (wild type, input cell lines), 
shMET or shLacZ for the transduced cell lines. Transduced 
and wild type cell lines U266 and INA6 cells were plated in 
complete RPMI medium onto 6-well culture plates at a con-
centration of 2 × 104/well, and then counted in specified 
time intervals to judge growth. The number of cells after 
24 h was used as the baseline and compared to the number 
of cells after 48, 72 and 96 h of incubation.
Analysis of a mute MET receptor  
in a mouse model using transduced  
U266 cell lines
For in vivo studies, 15 non-obese diabetic/severe com-
bined immunodeficiency (NOD/SCID) mice purchased 
from Jackson Laboratories, Bar Harbor, USA were used. 
This study was approved by the local ethics committee. 
The NOD/SCID mice were irradiated at 300 cGy using 
a GammaCell irradiator. The mice were divided into 
3 subgroups, 5 in each group, and after 24 h, the ocular 
sinus was injected with 5 × 106 cells of the following cell 
lines: wt-U266, shMET-U266 and shLacZ-U266. After 
the death of the mice, their long bones were isolated, 
fixed in paraformaldehyde, and then prepared in par-
affin blocks for slide mounting immunohistochemical 
staining.
Statistical analysis
Statistical analysis of the results was performed using 
GraphPad Prism 4.02 (GraphPad Software Inc., La Jolla, 
USA). Survival analysis of the mice was performed using 
the Kaplan-Meier analysis. The statistical significance 
of differences between groups was tested using the Stu-
dent’s t-test or one-way ANOVA at a significance level 
of p < 0.05.
Results
We observed MET receptor expression in myeloma cell 
lines both at the mRNA and protein levels. In order to 
investigate the presence of MET receptor mRNA in myelo-
ma cell lines, 3 independent experiments were performed 
using RT-PCR. There was no presence of MET receptor 
expression in blood mononuclear cells isolated from the 
umbilical cord as a negative control (Fig. 1).
Characteristics of transduced  
U266 and INA6 myeloma cell lines
The line shMET-U266 showed a significant decrease in 
mRNA expression for the MET gene compared to wt-U266 
(0.38 vs 8.63 au), and shMET-INA6 showed a significant 
decrease in mRNA expression for the MET gene compared 
to wt-INA6 (0.36 vs 6.0 au) (Fig. 2A). The mRNA expres-
sion for the MET gene in shLacZ-U266/INA6 confirms 
proper acting of the lentiviral construct. The decrease in 
MET mRNA was reflected in decreased expression of the 
MET receptor (Fig. 2B). Western blotting detected a signifi-
cant decrease in the amount of protein compared to MET 
Fig. 1. A – immunohistochemical staining of multiple myeloma cell lines 
for the presence of the MET receptor; B – (a) control cells, (b) U266 cells,  
(c) INA6 cells. Representative pictures, microscope magnification x200
Fig. 2. shMET-U266 showed a significant decrease in mRNA expression 
for the MET gene compared to wt-U266 (0.38 vs 8.63 au), and shMET-INA6 
showed a significant decrease in mRNA expression for the MET gene 
compared to wt-INA6 (0.36 vs 6.0 au)
A – mRNA expression for the MET gene in shLacZ-U266/INA6 confirms 
proper acting of the lentiviral construct; B – the decrease in MET 
mRNA was reflected in decreased expression of the MET receptor.
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output lines. The lentiviral construct directed against MET 
receptor mRNAs, can effectively reduce the MET receptor.
Blocking the HGF/MET axis did not affect the growth 
of cell lines U266 and INA6.
There was no difference in growth between wt-U266 
and shMET-U266, or between wt-INA6 and shMET-INA6 
(Fig. 3). Median survival rates were as follows: wt-U266 
– 40 days, shMET-U266 – 62 days (Fig. 4). Blocking the 
HGF/MET axis increased the survival of NOD/SCID mice, 
but the observed changes were not statistically significant 
(Fig. 5).
Discussion
The HGF/MET axis is involved in many physiological 
processes including growth, repression of intercellular ad-
hesion, cell migration, epithelial-mesenchymal transition 
(EMT), inhibition of apoptosis, proliferation and morpho-
genesis as well as in wound healing and tissue regenera-
tion.5,7,14–16 This axis is also important in oncogenesis and 
plays a significant role in the migration, proliferation and 
adhesion of various neoplastic cells. Overexpression or 
excessive activation of HGF/MET has been demonstrated in 
mesenchymal and epithelial tumors such as breast cancer, 
ovarian cancer, gastrointestinal tract cancer, lung cancer, 
prostate cancer, glioblastoma, sarcomas, and MM.17 MET 
is also partly responsible for the metastasis of tumor cells by 
increasing their migration, secretion of proteolytic enzymes, 
ability to survive in the blood vessels, and ability to remain 
in the capillary bed. Together with other mitogenic factors, 
such as the SDF-1-CXCR4 axis, it is involved in the coloniza-
tion of distant tissues by tumor cells, and stimulates their 
growth in microenvironments normally foreign to them.4
In  this study, we observed the expression of MET 
mRNA and MET protein in myeloma cell lines. Reports on 
the role of HGF/MET axis encourage research on the use 
of inhibitors of this axis in the treatment of various neo-
plastic diseases, including multiple myeloma. With re-
spect to the methods of inhibiting the axis of HGF/MET, 
one could consider inhibiting the attachment of HGF to 
the MET receptor, the prevention of dimerization of the 
MET receptor, the inhibition of the MET receptor tyro-
sine kinase, or the inhibition of the expression of HGF 
or MET.17 Blocking the interaction between the receptor 
and the ligand may occur after the application of com-
petitive antagonists of HGF or antibodies directed against 
HGF or MET. NK4 is a truncated form of HGF and com-
petes with it for binding at the MET receptor, and it does 
Fig. 3. Comparison of the growth rate of wild type cells and cells transduced with a lentiviral vector
A – comparison of cell lines wt-U266 and shMET-U266; B – comparison of lines wt-INA6 and shMET-INA6.
Fig. 4. Effect of reducing the expression of MET in U266 cells on the 
survival of NOD/SCID mice
Fig. 5. Survival expectancy of NOD/SCID mice – murine myeloma model
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not have the effect of receptor activation. In a study by 
Brockmann et al., it was demonstrated that NK4 inhibits 
glioblastoma growth in mice with implanted tumor cells 
via pro-apoptotic and anti-mitogenic mechanisms.17 NK4 
exhibited anti-cancer effects mainly due to the inhibi-
tion of invasion and metastasis as well as the inhibition of 
angiogenesis-dependent tumor growth.18 Du et al. showed 
reduced growth of myeloma cells in mice treated with 
NK4.19 Martens et al. demonstrated growth inhibition us-
ing anti-HGF neutralizing antibodies in a mouse model 
of glioblastoma.20 Vigna et al. also applied anti-MET an-
tibodies, which resulted in the inhibition of the growth of 
epithelial cancers.21 Recent studies have demonstrated that 
the use of angiotensin IV analog, norleual as an antagonist 
of HGF/MET, not only blocked its dimerization, but also 
inhibited HGF-dependent MET activation and had anti-
cancer activity.22 The semaphorin domain is necessary 
for MET receptor dimerization. Kong-Beltran et al. dem-
onstrated that recombinant soluble semaphorin domains 
block phosphorylation of the MET receptor, regardless 
of the presence or absence of HGF.23 To inhibit the MET 
tyrosine kinase and its signaling activity, low molecular 
weight inhibitors, such as geldanamycin, K252a, indoli-
none, and its analogs (17-AAG, 17-DMAG) or PHA665752 
were used.25–28 Hov et al., using PHA665752 small mol-
ecule acting directly on the receptor MET, observed the 
inhibition of cell proliferation, migration and adhesion 
in ANBL6 myeloma cell lines.24 To reduce the expression 
of MET and HGF, nonsense RNA or ribozymes can be 
used. Nonsense RNA or single-stranded DNA is a mol-
ecule consisting of a 15–25 nucleotide sequence, which 
can be used to induce degradation of mRNA or block its 
translation. Blocking the MET gene causes a decrease in 
expression of the MET receptor, thus inhibiting the growth 
of tumor cells.26 Abounader et al. demonstrated that ribo-
zymes, naturally occurring RNA molecules, can catalyze 
the specific cleavage of mRNA and reduce the expression 
of HGF and MET, resulting in the inhibition of activa-
tion of the MET receptor, and consequently the inhibition 
of colony formation and migration of tumor cells in vi-
tro.28 Que et al. revealed that the down-regulation of MET 
inhibits the proliferation and invasion of U266 myeloma 
cells, and increases their chemosensitivity to doxorubicin 
and bortezomib.29–31
Posttranscriptional gene silencing, a technique that is 
based on the phenomenon of RNA interference (RNAi) 
through siRNA, uses the natural process of gene expres-
sion dependent on double-stranded RNA. Translation 
of the mRNA is blocked by the introduction of siRNA with 
a sequence complementary to the target RNA. The use of an 
adenoviral vector encoding siRNA against MET in gastric 
cancer, prostate cancer and glioma cell lines resulted in 
decreased mitogenic activity. MET gene silencing resulted 
in the induction of apoptosis.32,33 In vitro siRNA can be 
delivered directly to the cell or in the form of vectors ex-
pressing siRNA.34,35 The use of viral systems allows for 
long-term silencing of the receptor and high reproduc-
ibility of results.
In  our study, in order to reduce the expression 
of mRNA for MET, a lentiviral model was used. Trans-
duction of U266 and INA6 cells using siRNA test vectors 
effectively silenced the expression of MET at both the 
mRNA and protein levels. Taulli et al. examined rhab-
domyosarcoma cells transduced with an siRNA lentiviral 
vector directed against the MET receptor, and observed 
not only inhibition of migration, but also decreased cell 
proliferation.36 In our study, we observed that the trans-
duced U266 and INA6 cell lines showed no differences 
in the rate of in vitro growth compared to the wt. Differ-
ences previously reported probably occurred due to the use 
of different experimental designs and different tumor types. 
Taulli et al. used a lentiviral vector in rhabdomyosarcoma 
cell lines induced by the presence of doxycycline in assess-
ing the impact of the MET receptor inhibition over 5 days 
of RNAi induction.36 In the present study, we used my-
eloma cell lines constitutively reduced in the expression 
of the MET receptor, and experiments were performed at 
least 3 weeks after the introduction of the vector. Hypo-
thetically, prolonged exposure to siRNA may allow cells 
to develop a mechanism to avoid apoptosis.
The  present study evaluated whether blocking the 
HGF/MET axis using lentiviral vectors may be a poten-
tial therapy to treat multiple myeloma. HGF is a potent 
chemoattractant for cells expressing the MET receptor 
on their surface. As a result of the increasing gradient of 
HGF, bloodborne myeloma cells settle in the bone mar-
row.37 A study by Teoh et al. demonstrated in U266 cells co-
cultured with mesenchymal stromal cells transfected with 
IL-6 siRNA a significant inhibition of cell growth, IL-6 
synthesis, and suggested potential use of RNA interfer-
ence-mediated therapy for multiple myeloma.38 Impaired 
response to the increased HGF gradient, caused by the re-
duction of the expression of the MET receptor, may influ-
ence the ability of tumor cells to migrate toward the bone 
marrow, which could hypothetically decrease neoplastic 
aggressiveness. Our experiments demonstrate that mice 
inoculated with myeloma cells with reduced expression of 
MET were characterized by higher median survival time 
than animals treated with wild type myeloma cell lines. 
The observed changes were not statistically significant; 
however, it should be noted that the test group of mice 
was not particularly large, and the observed difference in 
number of survival days, 40 vs 62, was evident. This gives 
us hope that a larger study group could lead to statistically 
significant results.
In conclusion, MET receptor expression is typical for 
myeloma cell lines. The  lentiviral construct directed 
against the MET receptor mRNAs can effectively reduce 
expression of the MET receptor in myeloma cells. Further 
studies are necessary to evaluate the effect of the reduction 
of MET receptor expression in multiple myeloma, focusing 
on animal models with a larger test group size.
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